Unique k-mer sequences for validating cancer-related substitution, insertion and deletion mutations.

Unique k-mer sequences for validating cancer-related substitution, insertion and deletion mutations.
复制标题

DOI:
10.1093/narcan/zcaa034
复制
发表时间:
2020-12
期刊:
影响因子:
5.1
通讯作者:
Ji HP
Ji HP
中科院分区:
其他
文献类型:
--
作者:
Lee H;Shuaibi A;Bell JM;Pavlichin DS;Ji HP

文献摘要

参考文献

相似文献

癌症基因组测序已经导致了重要的发现,例如癌症基因的鉴定。然而,在癌症基因组测序的分析中仍然存在挑战。一个重要的问题是,即使使用相同的基因组测序数据,由多个变异调用者鉴定的突变也经常不一致。对于插入和缺失突变,不同的调用者之间通常不存在一致性。识别体细胞突变涉及读段作图和变异识别,这是一个使用许多参数和模型调整的复杂过程。为了验证真突变的鉴定,我们开发了一种使用k-mer序列的方法。首先,我们描述了人类基因组中独特与非独特k-mer的景观。其次,我们开发了一个软件包,KmerVC,以验证给定的体细胞突变的测序数据。我们的程序基于来自匹配的正常和肿瘤序列的具有和不具有突变的k-mer频率的统计学显著差异来验证突变的发生。第三,我们在模拟和癌症基因组测序数据上测试了我们的方法。计数涉及突变的k-mer有效地验证了真阳性突变,包括以可重现的方式跨不同个体样品的插入和缺失。因此,我们展示了一种直接的方法,用于快速验证癌症基因组测序数据中的突变。
Cancer genome sequencing has led to important discoveries such as the identification of cancer genes. However, challenges remain in the analysis of cancer genome sequencing. One significant issue is that mutations identified by multiple variant callers are frequently discordant even when using the same genome sequencing data. For insertion and deletion mutations, oftentimes there is no agreement among different callers. Identifying somatic mutations involves read mapping and variant calling, a complicated process that uses many parameters and model tuning. To validate the identification of true mutations, we developed a method using k-mer sequences. First, we characterized the landscape of unique versus non-unique k-mers in the human genome. Second, we developed a software package, KmerVC, to validate the given somatic mutations from sequencing data. Our program validates the occurrence of a mutation based on statistically significant difference in frequency of k-mers with and without a mutation from matched normal and tumor sequences. Third, we tested our method on both simulated and cancer genome sequencing data. Counting k-mer involving mutations effectively validated true positive mutations including insertions and deletions across different individual samples in a reproducible manner. Thus, we demonstrated a straightforward approach for rapidly validating mutations from cancer genome sequencing data.
DOI: 10.1038/nbt.2862
发表时间: 2014-05
影响因子: 46.9
作者:
Patro, Rob;Mount, Stephen M.;Kingsford, Carl
通讯作者: Kingsford, Carl
DOI: 10.1371/journal.pgen.1002384
发表时间: 2011-12
期刊: PLoS genetics
影响因子: 4.5
作者:
de Koning AP;Gu W;Castoe TA;Batzer MA;Pollock DD
通讯作者: Pollock DD
使用下一代 DNA 测序数据进行变异发现和基因分型的框架。
DOI: 10.1038/ng.806
发表时间: 2011-05
期刊: Nature genetics
影响因子: 30.8
作者:
通讯作者: --
DOI: 10.1186/gm432
发表时间: 2013
期刊: Genome medicine
影响因子: 12.3
作者:
O'Rawe J;Jiang T;Sun G;Wu Y;Wang W;Hu J;Bodily P;Tian L;Hakonarson H;Johnson WE;Wei Z;Wang K;Lyon GJ
通讯作者: Lyon GJ
DOI: 10.1371/journal.pone.0040294
发表时间: 2012
期刊: PloS one
影响因子: 3.7
作者:
Rosenfeld JA;Mason CE;Smith TM
通讯作者: Smith TM